Altimmune, Inc. (ALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.35-0.30%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Manage and reduce operating losses: metric not reported.
Altimmune is advancing its pemvidutide clinical trials well. The Phase 3 trial starts in second half of 2026. This progress supports future growth. The company aims to manage operating losses but still faces challenges.
Altimmune is losing money and cut guidance recently. Operating losses remain large at -$24.2M in 2026-Q1. Dilution and share count increases hurt shareholder value. The stock is down 15% from its high.
The market expects about 92% revenue growth. Our fair value matches the consensus price of $0.71. We see risk from ongoing losses and dilution not fully priced in.
Breaks if: Operating loss worsens beyond -$24.2M in 2026-Q1
Breaks if: Phase 3 MASH trial start delayed beyond 2H 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it operates in a sector with favorable trends that could support its recovery.
The market seems to be pricing in a fragile situation, as the valuation is considered expensive despite the company's weak performance. There is an expectations gap that suggests investors are anticipating better outcomes than what has been delivered so far.
Fundamentals are likely to remain under pressure in the near term, given the company's ongoing losses and elevated risk profile. However, management is making progress in advancing clinical trials and strengthening its financial position through capital raises.
The thesis hinges on management's ability to execute on clinical trials and manage operating losses effectively. Additionally, external factors like sector performance and economic conditions will play a significant role in shaping the company's future.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. Additionally, the advancement of pemvidutide clinical trials in MASH, AUD, and ALD reinforces confidence in product development. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on progressing the clinical trials of pemvidutide for metabolic dysfunction-associated steatohepatitis.
Breaks if: Share count increases significantly beyond current levels
In the next 1 to 3 years, ALT's performance will depend on its clinical advancements and broader market conditions. Not investment advice.